
NICE has approved Amryt’s rare lipid disorder drug Myalepta (metreleptin), currently the only leptin replacement therapy available, for use within …
Pharmafocus talked to Joe Wiley, CEO and founder of Amryt Pharma as he retraced his journey from medical student in …

Recent data has shown that England is, on average, slower than Germany, France, Spain and Italy in making orphan medicinal …

